Search results (251)
« Back to NewsBiohackathons, boot-strapping and Innovate UK backing – how Evolvere Biosciences is tackling antimicrobial resistance
1 May 2024
A seminal study in The Lancet¹ estimates that in 2019 some 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths attributable to bacterial AMR. Evolvere is tackling this challenging unmet need using a platform combining synthetic biology, bioinformatics, and AI, designing new drugs plus generating AI models for other companies to license.
BiotechTV explores the BioEscalator's role in nurturing start-ups
30 April 2024
Brad Loncar visited the BioEscalator to learn more about how we support the growth of innovative medical science companies.
Integrated cancer biotech Infinitopes secures £12.8M seed financing to enhance its Precision Immunomics(TM) antigen discovery technologies to target five more cancers
30 April 2024
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1
CardiaTec joins the BioEscalator - AI in cardiovascular drug discovery
17 April 2024
The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.
MediMabBio - Two time zones, one mission
10 April 2024
Two clocks are visible behind the Chief Scientific Officer of MediMabBio, Dr Chris Willberg, as he sits in the company office at the BioEscalator – showing time zones seven hours apart, they are a reminder of how teams in Seoul and Oxford are working together to discover new treatments for cancer and autoimmune disease.
Granza Bio: Pioneering personalised and targeted cancer therapeutics
3 April 2024
The BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.
It started with a brainstorm
20 March 2024
Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.
Exogene announces strategic collaboration with Immunocore to engineer T-Cell receptors using artificial intelligence
4 March 2024
Exogene, a pioneer in the use of generative artificial intelligence (AI) for T-cell receptor (TCR) engineering, has entered into a research collaboration with industry leader Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.
Infinitopes has a double victory at the 15th Annual OBN Awards 2023
23 November 2023
The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.
BioEscalator Apprentice Laboratory Technician nominated for Intermediate & Advanced Apprentice Award
6 November 2023
Throughout her apprenticeship, Fabiha has shown remarkable determination in learning and mastering the skills required for her role.
Celebrating 5 years of the Oxford BioEscalator
15 October 2023
The BioEscalator recently marked its 5th anniversary with a celebration that showcased the impressive journeys of some of its current and graduated biotech companies.
Hutano Diagnostics acquired by EDX Medical Group
28 September 2023
We are delighted that BioEscalator resident start-up Hutano Diagnostics has announced its acquisition by Cambridge, UK-based EDX Medical Group PLC.
Oxford Silk Phage Technologies wins BioCap 2023 pitch competition
28 September 2023
Despite facing tough competition, Oxford Silk Phage Technologies impressed the judges with its presentation, earning the top spot in the competition.
Inspiring stories shared at The Africa Oxford Health Innovation platform programme
30 August 2023
The BioEscalator community engaged with the talented cohort of innovators from The Africa Oxford Health Innovation Platform (AfOx-HIP) programme, a collaborative initiative by the University of Oxford fostering innovation and entrepreneurship to address crucial health challenges in Africa.
BioEscalator Laboratory Manager nominated for Apprentice Manager Award
31 July 2023
Dr. Khwaja Islam's Apprentice Manager Award nomination shows his commitment to providing excellent apprenticeship training and cultivating a skilled workforce for the future.
Building bonds beyond the lab: BioEscalator's Party in the Park 2023
19 July 2023
The event provided an excellent opportunity for BioEscalator residents to connect and build relationships with their colleagues and neighbours outside of the workplace. It also offered a much-needed break from the daily work routine.
BioEscalator Pitch Battle 2023
12 July 2023
Pitching a business idea to potential investors is nerve-wracking for any entrepreneur. The pressure to effectively convey a company's vision, potential, and market viability can be overwhelming. However, for the innovative companies associated with the BioEscalator, this task became an opportunity to shine at the fourth annual BioEscalator Pitch Battle.
BioEscalator presented with LEAF Bronze Award at the Vice Chancellor’s Environmental Sustainability Awards 2023
19 June 2023
The BioEscalator, alongside resident company Alethiomics, was presented with the award, showing commitment towards sustainable practices.
Connecting startups to cutting-edge laboratory facilities in Oxford
18 May 2023
The BioEscalator and Oxford University Innovation teamed up to hold an event to showcase the state-of-the-art laboratory facilities at the University of Oxford to resident BioEscalator companies and start-ups from the Oxfordshire innovation ecosystem.
Alethiomics and Infinitopes shortlisted in the New Startup of the Year category for the Cancer Research Horizons Innovation & Entrepreneurship Awards 2022
5 December 2022
Alethiomics is uncovering new biology to discover and develop life-changing treatments for patients with blood cancer, and Infinitopes is identifying hidden tumour targets, enabling the creation of high-efficiency vaccines.